|
Market Closed -
Nasdaq
00:00:00 10/11/2026 +03
|
5-day change | 1st Jan Change | ||
| 37.82 USD | +1.52% |
|
+2.37% | -10.54% |
| 10-12 | UBS Initiates Coverage on Nektar Therapeutics With Neutral Rating, $53 Price Target | MT |
| 10-12 | Leerink Partners Initiates Nektar Therapeutics at Outperform, $130 Price Target | MT |
| Market Cap | 1.29B 1.15B 1.06B 963M 1.82B 121B 1.87B 12.69B 5.06B 64.81B 4.85B 4.74B 204B | P/E 2026 * |
-4.68x | P/E 2027 * | -3.6x |
|---|---|---|---|---|---|
| Enterprise Value | 683M 610M 561M 509M 965M 64.03B 989M 6.71B 2.68B 34.28B 2.56B 2.51B 108B | EV / Sales 2026 * |
16.3x | EV / Sales 2027 * | 16.4x |
| Free-Float |
99.62% | Yield 2026 * |
-
| Yield 2027 * | - |
| Markets | Quality | ||
|---|---|---|---|
Nasdaq
| NKTR | Delayed | |
CBOE
| NKTR | Real-time | |
|
Tradegate
| ITH0 | Real-time | |
|
Deutsche Boerse AG
| ITH0 | Delayed | |
|
Börse Stuttgart
| ITH0 | Delayed | |
|
Boerse Muenchen
| ITH0 | Real-time | |
|
Xetra
| ITH0 | Delayed |
Last Transcript: Nektar Therapeutics
| 1 day | +1.52% | ||
| 1 week | +2.37% | ||
| Current month | -2.69% | ||
| 1 month | -8.12% | ||
| 3 months | -50.54% | ||
| 6 months | -53.81% | ||
| Current year | -10.54% |
| 1 week | 35.76 |  | 39.19 |
| 1 month | 35.61 | | 40.98 |
| Current year | 33.4 | | 109 |
| 1 year | 33.4 | | 109 |
| 3 years | 6.19 | | 109 |
| 5 years | 6.19 | | 239.17 |
| 10 years | 6.19 | | 1,670.4 |
| Manager | Title | Age | Since |
|---|---|---|---|
Howard Robin
CEO | Chief Executive Officer | 73 | 01/01/2007 |
Linda Rubinstein
DFI | Director of Finance/CFO | 60 | 15/05/2026 |
| Chief Tech/Sci/R&D Officer | 52 | 01/07/2015 |
| Director | Title | Age | Since |
|---|---|---|---|
Roy Whitfield
BRD | Director/Board Member | 72 | 01/08/2000 |
Robert Chess
CHM | Chairman | 69 | 01/05/1992 |
Howard Robin
BRD | Director/Board Member | 73 | 01/02/2007 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 9/23/26 A | Free | Director | 6,000 | 0.0176% | ||
| 9/23/26 A | Free | Director | 6,000 | 0.0176% | ||
| 9/23/26 A | Free | Director | 6,000 | 0.0176% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +1.52% | +2.37% | -32.42% | +430.88% | 1.27B | |
| +2.24% | +8.40% | +58.47% | +69.00% | 66.7B | |
| +4.66% | +8.90% | +16.93% | +85.41% | 56.88B | |
| -0.60% | +1.73% | +24.32% | +94.40% | 56.53B | |
| +2.55% | +15.52% | +30.43% | +120.17% | 46.49B | |
| +2.58% | +7.89% | +32.49% | +45.30% | 44.8B | |
| +4.09% | +6.37% | +228.06% | +899.75% | 41.59B | |
| -0.47% | +9.38% | +27.53% | +52.40% | 35.35B | |
| +3.80% | -1.00% | +98.16% | +66.79% | 33.29B | |
| +1.48% | +6.21% | -38.80% | +395.73% | 25.1B | |
| Average | +2.18% | +6.21% | +44.52% | +225.98% | 41B | |
| Weighted average by Cap. | +2.29% | +7.26% | +53.48% | +182.33% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 41.82M 37.33M 34.35M 31.18M 59.08M 3.92B 60.55M 411M 164M 2.1B 157M 154M 6.61B | 53.42M 47.68M 43.87M 39.82M 75.46M 5.01B 77.34M 525M 209M 2.68B 200M 196M 8.44B |
| Net income | -246M -220M -202M -184M -348M -23.1B -357M -2.42B -965M -12.37B -925M -905M -38.94B | -363M -324M -298M -270M -512M -33.99B -525M -3.56B -1.42B -18.2B -1.36B -1.33B -57.31B |
| Net Debt | -608M -543M -500M -453M -859M -57.02B -881M -5.98B -2.38B -30.53B -2.28B -2.23B -96.15B | -415M -371M -341M -310M -587M -38.92B -601M -4.08B -1.63B -20.84B -1.56B -1.53B -65.63B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 09/11/26 | $37.83 | +1.52% | 684,335 |
| 06/11/26 | $37.26 | +3.07% | 686,445 |
| 05/11/26 | $36.15 | -6.06% | 726,552 |
| 04/11/26 | $38.48 | +1.91% | 498,473 |
| 03/11/26 | $37.76 | +2.19% | 429,007 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
- Stock Market
- Stocks
- NKTR Stock
Select your edition
All financial news and data tailored to specific country editions
